Valacyclovir Hydrochloride Articles
US FDA approves Actavis generic copy of GSK’s Valtrex and Hi-Tech’s lidocaine; Cephalon wins Fentora patent case
25 March 2011
Ranbaxy back in black in fourth quarter as US sales soar
26 February 2010
GlaxoSmithKline to refocus some research and seek efficiencies, despite posting huge 4th-qtr 2009 profits rise; applause from Science Minister
5 February 2010
Big upside for Ranbaxy as it launches generic version of Glaxos herpes drug Valtrex
27 November 2009
Teva gets tentative US OK for generic Valtarex
15 October 2007
Ranbaxy and GSK settle over Valtrex
6 August 2007
GSK posts solid results for 1st-qtr 2007 with a 14% EPS rise despite US generic pressure
30 April 2007
Ranbaxy gains final approval for generic valacyclovir
12 February 2007
GSK's full-year 2006 turnover up 7%
12 February 2007
GSK seeks to block generic Valtrex in USA
12 February 2007
GSK EPS rises 10% on 6% sales growth
8 August 2005
GlaxoSmithKline sees 10% EPS rise on 6% sales growth
1 August 2005
Merix sues GSK over Abreva and Valtrex promotion
28 March 2005
GSK results in line with company guidance; shares fall on 16% drop in 4th-qtr income
23 February 2004
Valtrex backed in USA for new indication
19 May 2003
Stock commentary - week to Feb 10 - Europe
17 February 2003
Update: GSK 2002 results boosted by 13% growth in US sales
17 February 2003
GlaxoSmithKline 2002 results boosted by 13% growth in US sales
17 February 2003
GSK's Valtrex could be one-day cold sore drug
12 August 2002
France rejects Flamel's filing for Genvir
3 October 2001
GW pulls out of one Cantab herpes deal
18 August 2000
Glaxo SmithKline, an R&D powerhouse and global number one
17 January 2000
US 2nd-Qtr Rx DTC Spending Rises 25%
6 November 1998
UK Launch For GW's OD Genital Herpes Drug
28 July 1998
Famvir Trial To Test Latency Prevention
15 April 1998
World Antiviral Market Forecasts To 2005
20 February 1998
Glaxo Wellcome Profits Hit By Strength Of Sterling
19 February 1998
GW-SB Merger Will Create R&D Superpower
5 February 1998
First EU Approval For GW's Valaciclovir
29 January 1998
Global Anti-HIV Market To Top $5 Billion In 2005
21 January 1998
Famvir Potential Grows With New Data
15 October 1997
GW's Combivir Approved In The USA For HIV
1 October 1997
FDA Sets New Rules For Radio/TV Pharma Ads
12 August 1997
Underlying Growth Healthy At GW Despite Strong L
6 August 1997
Penciclovir Launched In USA
5 May 1997
Glaxo Wellcome 1996 Product Performance
17 March 1997
Zocor "Will Be World's Top-Selling Drug In 2005"
13 January 1997
Correction in GW share Price An Over-reaction?
22 April 1996
Valtrex Prevents Herpes Recurrences
1 April 1996
NCEs In 1995: A Good Range Of Novel Drugs
29 January 1996
GW's Valtrex: news
29 January 1996
FDA Year-End Approvals Round-Up
8 January 1996
European Stock Comment
8 January 1996
Glaxo Wellcome Unveils Revamped Pipeline
20 November 1995
Glaxo Wellcome Revamps R&D To Treble Productivity
13 November 1995
Glaxo Wellcome: Valtrex news
6 November 1995
UK Code Of Practice Amendments, New Report
25 September 1995
Famvir Gains Once-Daily Product license
18 September 1995
Testing Times Ahead For Glaxo Wellcome
18 September 1995
Glaxo Wellcome: Building For The Long Term
21 August 1995
EUROPEAN STOCK COMMENT
3 July 1995
FDA Approves Glaxo Wellcome's Valtrex
3 July 1995
Valtrex Launched In Sweden; Genital Herpes Data
3 April 1995
Valtrex Trial Stopped Due To XS Mortality
27 February 1995
Robb Claims Wellcome Is Undervalued By Glaxo
20 February 1995
Glaxo, Wellcome Product Lines Are Complementary
6 February 1995
Valtrex Launched In Its First Markets
6 February 1995
New Chemical Entities Round-Up For 1994
6 February 1995
FDA C'tee Gives Thumbs Down For OTC Zovirax
23 January 1995
Wellcome, Hoechst Copromotion Deal
2 January 1995
Burroughs Wellcome Outlook Reviewed
19 December 1994
New Data On Antiherpetics Presented At ICAAC
17 October 1994
European Stock Comment
17 October 1994
Wellcome Stops Campath-1H Development
3 October 1994
Four-Month Results At Wellcome As Expected
25 July 1994
SB Sets US Price For Famvir At Same Level As Zovirax
18 July 1994
Wellcome Files First PLAs for Valaciclovir
18 July 1994
WELLCOME'S SHARE PRICE WOES
4 April 1994
MORE ON NETIVUDINE WITHDRAWAL
4 April 1994
WELLCOME "TOO FOCUSED" FOR INDEPENDENCE
24 January 1994
FAMCICLOVIR APPROVED IN ITS FIRST MARKET
20 December 1993
WORLD MARKET FOR ANTI-INFECTIVES
15 November 1993
ANTIVIRAL CLASH LOOMS AS ICAAC DATA PRESENTED
25 October 1993
Showing 1-90 of 90 articles
- 1
- Novo Nordisk's diabetes drug Victoza produced 8% weight loss in Ph III obesity trial
- Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
- Positive new data on Novartis' Galvus in elderly type 2 diabetes patients
- Proposal to list Roche's Neulastim and Actemra in New Zealand
- Johnson & Johnson expects 10 NDA filings by 2017, saying pharma sector poised for growth
